Ifinatamab deruxtecan
| Clinical data | |
|---|---|
| Other names | DS-7300 |
| ATC code | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ifinatamab deruxtecan (DS-7300) is an experimental anti-cancer treatment developed by Merck and Daiichi Sankyo. It is an antibody–drug conjugate that "consists of an anti-B7-H3 antibody linked with a DNA topoisomerase I inhibiting anti-tumor agent".[1][2]
Ifinatamab-DXd is in phase III clinical trials for extensive stage small cell lung carcinoma (EC-SCLC) from 2024 onward.[3] I-DXd progressed directly from Phase I to Phase III, due to exceptional response rates (>65% ORR) in a difficult to treat cancer. I-DXd is also in Phase III trials for metastatic castration resistant prostate cancer from 2025[4]
References
- ^ Katsumata L, Deguchi T, Hasegawa J, Yamato M, Nishiya Y, Watanabe A, et al. (4 April 2023). "Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization". Cancer Research. 83 (7_Supplement): 4891. doi:10.1158/1538-7445.AM2023-4891. S2CID 259620618.
- ^ Patel M, Doi T, Koyama T, Falchook G, Friedman C, Piha-Paul S, et al. (October 2023). "690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study". Annals of Oncology. 34: S481–S482. doi:10.1016/j.annonc.2023.09.1876. S2CID 264385889.
- ^ "IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer" (Press release). Merck. 1 August 2024. Retrieved 29 September 2025.
- ^ "IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer" (Press release). Merck. 18 June 2025. Retrieved 29 September 2025.